Molecular Partners AG
MP0317
advanced cancer types
Resolved
7days ago
Phase 2 readout · ~ Jun 30, 2026 estimated
What's at stake
Phase 2 trial results for MP0317 in advanced cancer types are due ~ Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 14h ago
“The study is a randomized, multicenter study in France and aims to recruit 75 patients (with a 2to1 design, including 50 patients in the experimental arm, and 25 in the control arm).”